Toronto-based startup Soricimed Biopharma is developing drug conjugates for cancer treatment, using its targeted oncology drug, SOR-C27, to carry a chemotherapy payload directly to the tumor. The privately owned company will be working with Mount Allison University on the project, which aims to cut the dose of cancer drug needed and so reduce potential side effects. Jack Stewart, Soricimed Biopharma's chief scientific officer and chair, says: "Given the highly targeted way in which our peptides bind to cancer cells, we hypothesize that lower doses of chemotherapy will be required if attached to SOR-C27 as a payload." Press release